公开(公告)号：US20220289807A1

公开(公告)日：2022-09-15

申请号：US17634685

申请日：2020-08-13

Applicant: AMGEN INC.

Inventor： Darren L. BATES ,  Sue J. SOHN ,  Hannah Beth CATTERALL ,  Zhulun WANG

IPC: C07K14/55 ,  A61K38/20 ,  A61P3/10 ,  A61P37/06

Abstract: Provided herein are IL-2 muteins and IL-2 mutein Fc fusion molecules that preferentially expand and activate cells and are amenable to large scale production. Also provided herein are methods of making and using the compositions of the present invention.

公开(公告)号：US20220025059A1

公开(公告)日：2022-01-27

申请号：US17332578

申请日：2021-05-27

Applicant: AMGEN INC.

Inventor： Junming YIE ,  Donghui SHI ,  David J. LLOYD ,  Jinghong WANG ,  Glenn N. SIVITS, JR. ,  Murielle M. VENIANT-ELLISON ,  Renee KOMOROWSKI ,  Neeraj AGRAWAL ,  Darren L. BATES ,  Brandon C. P. CLAVETTE ,  Ian N. FOLTZ ,  Shu-yin HO ,  Christopher MURAWSKY ,  Xiaoshan MIN ,  Zhulun WANG

IPC: C07K16/28

Abstract: Methods of treating metabolic diseases and disorders using an antigen binding protein specific for the GIPR polypeptide are provided. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy. In certain embodiments the antigen binding protein is administered in combination with a GLP-1 receptor agonist.

公开(公告)号：US20220402985A1

公开(公告)日：2022-12-22

申请号：US17836425

申请日：2022-06-09

Applicant: Amgen Inc.

Inventor： Darren L. BATES ,  Zhi LIU ,  TaeWeon LEE ,  Mark L. MICHAELS ,  Zhulun WANG

IPC: C07K14/485 ,  A61P9/10

Abstract: The present invention relates to engineered neuregulin-1 variants that selectively activate ErbB4 receptors but do not activate ErbB3 receptors. The invention also provides methods for using such variants to treat heart failure.

公开(公告)号：US20210087286A1

公开(公告)日：2021-03-25

申请号：US16623750

申请日：2018-06-20

Applicant: AMGEN INC.

Inventor： Darren L. BATES ,  Donghui SHI ,  David J. LLOYD ,  Pavel BONDARENKO ,  Mark L. MICHAELS ,  Todd HAGER ,  Xiaoshan MIN ,  Aiko UMEDA ,  Irwin CHEN ,  Zhulun WANG

IPC: C07K16/28 ,  A61K38/26

Abstract: Methods of treating metabolic diseases and disorders using an antigen binding protein specific for the GIPR polypeptide are provided. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy. In certain embodiments the antigen binding protein is administered in combination with a GLP-1 receptor agonist.

公开(公告)号：US20250129160A1

公开(公告)日：2025-04-24

申请号：US18566228

申请日：2022-06-02

Applicant: AMGEN RESEARCH (MUNICH) GmbH ,  AMGEN INC.

Inventor： Johannes BROZY ,  Christoph DAHLHOFF ,  Tobias RAUM ,  Jochen S. PENDZIALEK ,  Lisa WINKEL ,  Marcus MUENZ ,  Nathan William PIERCE ,  Agnieszka KIELCZEWSKA ,  Wentao CHEN ,  Darren L. BATES ,  Claudia BLUEMEL ,  Jonas Karl-Josef HONER

IPC: C07K16/28

Abstract: The present invention provides single chain T cell engager (TCE) molecules having an scFab that binds a target antigen and an scFv that binds CD3, and TCE molecules that bind CCR8 and CD3. Methods of treating cancer are also provided.

公开(公告)号：US20170275370A1

公开(公告)日：2017-09-28

申请号：US15387542

申请日：2016-12-21

Applicant: AMGEN INC.

Inventor： Junming YIE ,  Donghui SHI ,  David J. LLOYD ,  Jinghong WANG ,  Glenn N. SIVITS, JR. ,  Murielle M. VENIANT-ELLISON ,  Renee KOMOROWSKI ,  Neeraj AGRAWAL ,  Darren L. BATES ,  Brandon C. P. CLAVETTE ,  Ian N. FOLTZ ,  Shu-yin HO ,  Christopher MURAWSKY ,  Xiaoshan MIN ,  Zhulun WANG

IPC: C07K16/28 ,  A61K39/395 ,  A61K38/26 ,  A61K9/00

CPC classification number: C07K16/2869 ,  A61K9/0019 ,  A61K38/1703 ,  A61K38/26 ,  A61K39/3955 ,  A61K2039/505 ,  A61K2039/54 ,  C07K2299/00 ,  C07K2317/21 ,  C07K2317/32 ,  C07K2317/33 ,  C07K2317/41 ,  C07K2317/52 ,  C07K2317/71 ,  C07K2317/76 ,  C07K2317/92 ,  A61K2300/00

Abstract: Methods of treating metabolic diseases and disorders using an antigen binding protein specific for the GIPR polypeptide are provided. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy. In certain embodiments the antigen binding protein is administered in combination with a GLP-1 receptor agonist.